Physician profile
Richard Reutter
NPI 1225089923
$6,290.54
in general payments reported to CMS, 2019-2025
16 companies · $2,371 in 2025
The $2,371 reported for 2025 was more than what 97% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $324 · 2020: $2,185 · 2021: $412 · 2022: $371 · 2023: $341 · 2024: $286 · 2025: $2,371.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,908 · Food and Beverage: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,908.00 |
| Food and Beverage | $1,090.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $1,988.17 | 2019-2021 | |
| Purdue Pharma L.P. | $1,908.00 | 2025 | |
| Supernus Pharmaceuticals, INC. | $683.61 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $366.92 | 2020-2025 | Onyda Xr, Dyanavel Xr |
| Corium, LLC | $296.31 | 2022-2025 | Azstarys |
| Neos Therapeutics, LP | $279.32 | 2019-2023 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $252.78 | 2019-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $167.60 | 2019-2022 | |
| Rhodes Pharmaceuticals L.P. | $161.86 | 2019 | |
| Collegium Pharmaceutical, INC. | $60.24 | 2025 | Jornay Pm |
| Acadia Pharmaceuticals INC | $34.62 | 2023 | Daybue |
| Genentech USA, INC. | $26.15 | 2021-2022 | |
| Soleno Therapeutics, INC. | $20.32 | 2025 | Vykat Xr |
| Sunovion Pharmaceuticals INC. | $15.88 | 2020 | |
| Vertical Pharmaceuticals, LLC | $14.54 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $14.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Reutter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.